drugset / Trial / NCT07170644
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Phase 2
Active not recruiting
20 enrolled
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.
Timeline
- Start
- 2025-08-08
- Primary completion
- 2027-05-28
- Completion
- 2029-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | 150 mg | Oral |